Ftse Mib
34.676,17
1,15%
DAX
19.254,97
1,03%
S&P 500
5.728,80
0,41%
NASDAQ
18.239,92
0,80%
Bitcoin
69.507,65
0,04%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Akero Therapeutics Inc (AKRO) Akero Therapeutics Inc (AKRO) Notizie

AKRO

Akero Therapeutics (AKRO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AKRO
DataOraFonteTitoloSimboloCompagnia
02/11/202401:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
01/11/202421:46Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKROAkero Therapeutics Inc
21/10/202413:00GlobeNewswire Inc.Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024NASDAQ:AKROAkero Therapeutics Inc
01/10/202403:37PR Newswire (US)INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law FirmNASDAQ:AKROAkero Therapeutics Inc
30/09/202413:00GlobeNewswire Inc.Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual ConferenceNASDAQ:AKROAkero Therapeutics Inc
09/09/202413:00GlobeNewswire Inc.Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASHNASDAQ:AKROAkero Therapeutics Inc
28/08/202422:05GlobeNewswire Inc.Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:AKROAkero Therapeutics Inc
09/08/202413:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AKROAkero Therapeutics Inc
09/08/202413:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKROAkero Therapeutics Inc
09/08/202413:00GlobeNewswire Inc.Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AKROAkero Therapeutics Inc
11/06/202413:00GlobeNewswire Inc.Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASHNASDAQ:AKROAkero Therapeutics Inc
08/06/202414:15GlobeNewswire Inc.Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024NASDAQ:AKROAkero Therapeutics Inc
29/05/202413:00GlobeNewswire Inc.Akero Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:AKROAkero Therapeutics Inc
10/05/202422:57Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:AKROAkero Therapeutics Inc
10/05/202413:00GlobeNewswire Inc.Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AKROAkero Therapeutics Inc
08/05/202413:00GlobeNewswire Inc.Akero Therapeutics to Present at the BofA Securities 2024 Health Care ConferenceNASDAQ:AKROAkero Therapeutics Inc
30/04/202414:00GlobeNewswire Inc.Akero Therapeutics Appoints Scott Gangloff as Chief Technology OfficerNASDAQ:AKROAkero Therapeutics Inc
08/03/202422:02GlobeNewswire Inc.Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:AKROAkero Therapeutics Inc
07/03/202422:01GlobeNewswire Inc.Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and HepatologyNASDAQ:AKROAkero Therapeutics Inc
06/03/202423:16Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AKROAkero Therapeutics Inc
06/03/202403:13GlobeNewswire Inc.Akero Therapeutics Announces Pricing of Public Offering of Common StockNASDAQ:AKROAkero Therapeutics Inc
05/03/202412:05IH Market NewsAMD Hits Regulatory Roadblock, GitLab’s Stock Tumbles on Disappointing Earnings, and Latest NewsNASDAQ:AKROAkero Therapeutics Inc
04/03/202422:21GlobeNewswire Inc.Akero Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:AKROAkero Therapeutics Inc
04/03/202412:00GlobeNewswire Inc.Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY StudyNASDAQ:AKROAkero Therapeutics Inc
29/02/202422:42Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AKROAkero Therapeutics Inc
29/02/202414:00GlobeNewswire Inc.Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASHNASDAQ:AKROAkero Therapeutics Inc
29/02/202413:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AKROAkero Therapeutics Inc
29/02/202413:00GlobeNewswire Inc.Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AKROAkero Therapeutics Inc
14/02/202403:40Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AKROAkero Therapeutics Inc
03/01/202414:15GlobeNewswire Inc.Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AKROAkero Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AKRO

La tua Cronologia

NYSE
LXU
LSB Industries
USOTC
ELUXY
AB Electrolux (PK)
LSE
34ZD
Anz Nz.25
BIT
CLUS
Lyxor Msci Usa Clmt Chan...
LSE
FNX
Fonix
USOTC
FNNNF
Finnair OYJ (PK)
TSXV
AVR
Avaron Mining
TSX
ENB.PF.K
Enbridge
NASDAQ
WPRT
Westport Fuel Systems
ASX
CLE
Cyclone Metals
ASX
BDG
Black Dragon Gold
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network